Modeling the Future Burden of Stroke in the Netherlands

Struijs, Jeroen N.; Genugten, M.L.L. van; Evers, Silvia M. A. A.; Ament, André; Baan, Caroline A.; Bos, G.A.M. van den

doi:10.1161/01.str.0000173221.37568.d2

Cited by 77 publications

(68 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…21 Hypertension has been linked to HIV serostatus and to treatment. 22 Chronic high BP increases the risk of damage to target organs and is associated with cerebrovascular disease (strokes, white matter hyperintensities, and cortical atrophy), 23,24 subclinical renal dysfunction, 25 left ventricular hypertrophy, 26 increased IMT (as a marker of atherosclerosis), 25 and retinal arteriolar narrowing.…”

Section: Resultsmentioning

confidence: 99%

Vascular risk factors, HIV serostatus, and cognitive dysfunction in gay and bisexual men

et al. 2009

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Vascular risk factors, HIV serostatus, and cognitive dysfunction in gay and bisexual men

et al. 2009

View full text Add to dashboard Cite

show abstract

“…The CDM is a tool to describe the morbidity and mortality effects of risk factors for chronic diseases, including smoking and overweight and has been used for projections of risk factor and disease prevalence and cost effectiveness analysis (van Baal et al, 2006(van Baal et al, , 2007aFeenstra et al, 2001Feenstra et al, , 2005Struijs et al, 2005;Jacobs-van der Bruggen et al, 2007). The model describes the life course of cohorts in terms of changes between risk factor classes and changes between disease states over time.…”

Section: Acknowledgementsmentioning

confidence: 99%

Economic evaluation and the postponement of health care costs

et al. 2011

View full text Add to dashboard Cite

Economic evaluation and the postponement of health care costs van Baal, P.H.; Feenstra, T.L.; Polder, Johan; Hoogenveen, R.T.; Brouwer, W. Published in: Health Economics Document version:Publisher's PDF, also known as Version of record General rightsCopyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.-Users may download and print one copy of any publication from the public portal for the purpose of private study or research -You may not further distribute the material or use it for any profit-making activity or commercial gain -You may freely distribute the URL identifying the publication in the public portal Take down policyIf you believe that this document breaches copyright, please contact us providing details, and we will remove access to the work immediately and investigate your claim. SUMMARYThe inclusion of medical costs in life years gained in economic evaluations of health care technologies has long been controversial. Arguments in favour of the inclusion of such costs are gaining support, which shifts the question from whether to how to include these costs. This paper elaborates on the issue how to include cost in life years gained in cost effectiveness analysis given the current practice of economic evaluations in which costs of related diseases are included. We combine insights from the theoretical literature on the inclusion of unrelated medical costs in life years gained with insights from the so-called 'red herring' literature. It is argued that for most interventions it would be incorrect to simply add all medical costs in life years gained to an ICER, even when these are corrected for postponement of the expensive last year of life. This is the case since some of the postponement mechanism is already captured in the unadjusted ICER by modelling the costs of related diseases. Using the example of smoking cessation, we illustrate the differences and similarities between different approaches. The paper concludes with a discussion about the proper way to account for medical costs in life years gained in economic evaluations.

show abstract

“…5 In addition, some of these projections were based on stroke mortality trends in the 1980s or early 1990s. 6 Taking into account more recent trends can, however, change future perspectives. Moreover, to create a stable empirical basis for projections of future trends, it is important to consider stroke mortality trends over a long span of years.…”

mentioning

confidence: 99%